What Ginkgo Biloba Actually Does for Your Eyes

You have seen the name on supplement labels. You have heard it mentioned alongside memory and circulation. Maybe you are already taking it. But ask most people what ginkgo biloba actually does for your eyes and you will get a shrug.

That is understandable. Ginkgo biloba is one of the most studied herbal supplements in the world, and most of the coverage focuses on cognitive health. The eye health angle gets less attention. So let us fix that.

This post breaks down the two biological mechanisms behind ginkgo biloba's relevance to eye health, walks through what the clinical trials have actually found, and explains what the research means for people who are thinking about their long-term vision health.

What Is Ginkgo Biloba, and Why Does It Show Up in Eye Supplements?

Ginkgo biloba is one of the oldest living tree species on earth, unchanged for roughly 200 million years. The leaves have been used in traditional Chinese medicine for centuries, and modern standardized extracts have been studied extensively since the 1960s.

The standardized extract, usually called GBE, contains two main classes of active compounds: flavonoids and terpenoids (specifically ginkgolides and bilobalide). These are not the same thing as the crude leaf. Quality eye supplements use standardized GBE to ensure consistent concentrations of these active compounds with every dose.

Both classes of compounds have been studied for their effects on oxidative stress, inflammation, and blood flow. Those three mechanisms are exactly why ginkgo ends up in eye health formulations. Let us look at each one.

The Two Ways Ginkgo Biloba May Support Your Eyes

As a Free-Radical Scavenger

Your retina is under constant oxidative attack. Light exposure triggers the production of reactive oxygen species (free radicals) as a normal byproduct of the visual cycle. The photoreceptors in your outer retina have the highest metabolic rate of any tissue in the human body, and that intense energy use generates oxidative byproducts continuously throughout your waking hours.

Ginkgo's flavonoids are potent free-radical scavengers. They neutralize reactive oxygen species before those molecules can damage cell membranes, DNA, and the delicate structures of the photoreceptors and retinal ganglion cells. A 2025 review in the Journal of Dietary Supplements described standardized GBE as having 'potent antioxidant, anti-inflammatory, and neuroprotective properties' that are relevant to glaucoma, diabetic retinopathy, and age-related macular degeneration. To understand how this fits into the broader picture of cellular energy and optic nerve health, the mechanisms complement each other: antioxidants protect cells, while energy substrates keep them running.

As a Supporter of Ocular Blood Flow

The second mechanism is vascular. Ginkgo biloba has been shown to dilate blood vessels and reduce the viscosity of blood, two effects that may improve the flow of blood to the optic nerve.

This matters because reduced blood flow to the optic nerve is increasingly recognized as a contributing factor in glaucoma, particularly in normal-tension glaucoma (NTG). NTG is a form of glaucoma where the optic nerve continues to sustain damage even when eye pressure is completely normal. The leading hypothesis is that impaired vascular supply to the nerve plays a significant role. Ginkgo's vasodilatory properties make it biologically relevant here in a way that many other supplements are not.

What Does the Research Actually Show?

Here is where it gets honest. The clinical evidence is genuinely mixed, and any account of ginkgo biloba that ignores that is not giving you the full picture.

Most of the human research on ginkgo and eye health has focused on normal-tension glaucoma, and the results have not consistently aligned.

The Studies That Found a Benefit

The landmark study was published in Ophthalmology in 2003 by Quaranta and colleagues. In a prospective, randomized, double-blind, placebo-controlled crossover trial, 27 patients with normal-tension glaucoma received 40 mg of GBE three times daily (120 mg/day) for four weeks. After GBE treatment, visual field indices improved significantly: mean deviation improved from 11.40 dB to 8.78 dB, and corrected pattern standard deviation improved from 10.93 dB to 8.13 dB (both P = 0.0001). Eye pressure did not change, suggesting the effect was neuroprotective, not pressure-related.

A longer-term retrospective study published in the Journal of Glaucoma in 2013 by Lee and colleagues followed 42 NTG patients on 80 mg GBE twice daily (160 mg/day) over an average of 12.3 years. Before GBE treatment, the visual field deterioration rate was -0.619 dB per year. After starting GBE, that rate slowed significantly to -0.379 dB per year (P < 0.001). The effect was particularly notable in the superior central visual field, which is a clinically significant area.

The Studies That Found No Benefit

A well-designed randomized crossover trial published in Investigative Ophthalmology & Visual Science in 2014 by Guo and colleagues at Zhongshan Ophthalmic Center found no significant improvement. Thirty-five NTG patients received the same 40 mg GBE three times daily dose used in the Quaranta study, for the same four-week duration. Visual field mean deviation and contrast sensitivity did not differ between GBE and placebo (P > 0.2 for all outcomes). The study had 80% power to detect an effect as large as the one Quaranta reported, meaning it was well-designed enough to find a benefit if one existed at that size.

The most recent clinical data comes from a 2025 study in the Canadian Journal of Ophthalmology by Hodgson and colleagues. Using optical coherence tomography angiography (OCT-A), which measures blood flow with greater precision than prior methods, they gave 17 glaucoma patients 120 mg GBE twice daily (240 mg/day, a higher dose) for four months and found no significant improvement in macular perfusion density. Peripapillary perfusion, the blood flow around the optic disc, actually showed a small but statistically significant decrease. The authors called for larger, longer studies to interpret these findings.

Making Sense of the Discrepancy

The honest answer is that the studies differ in important ways: patient populations (Italian versus Chinese cohorts), study durations (4 weeks versus 4 months), doses (120 mg versus 240 mg/day), and measurement tools (visual field tests versus OCT-A). None of them was a large-scale randomized controlled trial. The Quaranta study had 27 patients. The Guo study had 35. These are early-stage clinical investigations, not definitive answers.

What the evidence supports, taken together, is this: ginkgo biloba has real biological activity that is plausibly relevant to eye health. Whether that activity translates into meaningful clinical benefit in glaucoma patients, at what dose, and over what time period, remains an open question. Researchers continue to investigate.

What Does This Mean for You?

If you have glaucoma or are at risk, the standard message has not changed: work closely with your eye doctor. Pressure management and monitoring are the foundation of glaucoma care. No supplement changes that.

What the ginkgo biloba research does represent is a serious scientific conversation about neuroprotection in glaucoma, one that parallels the research on nicotinamide and optic nerve support that we covered in our breakdown of the AAO position statement on glaucoma supplementation. The common thread across all of these studies is the question of how to support the health of retinal ganglion cells and the optic nerve beyond pressure control alone.

For people who are proactive about their eye health and already following their doctor's recommendations, ginkgo biloba is one of several evidence-informed ingredients that researchers have studied in this context.

The Bigger Picture

Ginkgo biloba is not a magic bullet. The clinical trials have produced mixed results, and honest interpretation of the evidence requires saying that out loud. But the biological rationale is real. An ingredient with potent antioxidant activity and vasodilatory properties is biologically relevant to a tissue that runs hotter than almost anything else in the body.

Sight Guard includes ginkgo biloba at 60 mg as one of five ingredients formulated to support optic nerve health and cellular energy in the eye. It is part of a multi-ingredient approach designed to complement your care, not replace it. If you are curious about the full science behind Sight Guard's formulation, you can explore it on our product page. Talk to your eye doctor before adding any supplement to your routine, particularly if you are on blood-thinning medications, as ginkgo biloba can affect platelet function.

The story of ginkgo biloba and the eye is still being written. The research that exists gives us enough to take it seriously, and enough to stay honest about what it has not yet proven.

1. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003;110(2):359-62. PMID: 12578781. DOI: 10.1016/S0161-6420(02)01745-1

2. Lee J, Sohn SW, Kee C. Effect of Ginkgo biloba extract on visual field progression in normal tension glaucoma. Journal of Glaucoma. 2013;22(9):780-4. PMID: 22595937. DOI: 10.1097/IJG.0b013e3182595075

3. Guo X, Kong X, Huang R, et al. Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial. Investigative Ophthalmology & Visual Science. 2014;55(1):110-6. PMID: 24282229. DOI: 10.1167/iovs.13-13168

4. Hodgson K, Palakkamanil MM, Zhang A, et al. Effect of ginkgo biloba extract on macula and peripapillary perfusion examined using optical coherence tomography angiography. Canadian Journal of Ophthalmology. 2025;60(4):e566-e571. PMID: 39961352. DOI: 10.1016/j.jcjo.2025.01.015

5. Thomas JO, Idowu IM. Phytochemicals in Ginkgo biloba for age-related eye disease: a review. Journal of Dietary Supplements. 2025;22(6):907-938. PMID: 40947728. DOI: 10.1080/19390211.2025.2560365

6. Wang LH, Huang CH, Lin IC. Advances in neuroprotection in glaucoma: pharmacological strategies and emerging technologies. Pharmaceuticals (Basel). 2024;17(10). PMID: 39458902. DOI: 10.3390/ph17101261

7. Sim RH, Sirasanagandla SR, Das S, Teoh SL. Treatment of glaucoma with natural products and their mechanism of action: an update. Nutrients. 2022;14(3):534. PMID: 35276895. DOI: 10.3390/nu14030534